Minireviews
Copyright ©The Author(s) 2023.
World J Hepatol. Mar 27, 2023; 15(3): 364-376
Published online Mar 27, 2023. doi: 10.4254/wjh.v15.i3.364
Table 1 Clinical data from various studies, n (%)
Ref.
Kelgeri et al[9], 2022
Cates et al[10], 2022
Marsh et al[11], 2022
Baker et al[12], 2022
Cumulative data
Demographic data
CountryUKUSAScotland, UKAlabama, USA
Number of patients44296139362
Age (yr), median (range)4 (1-7)2.2 (0–9.7)3.9 (3-5)2 (1.66-5.7)3 (0-9.7)
Male/female ratio0.83:11.42:11.2:10.28:11.3:1
Clinical findings
Jaundice 41 (93)71/123 (57.7)8/9 (88.9)8/9 (88.9)128/185 (69)
Vomiting24 (54)76/123 (61.8)4/4 (100)7/9 (77.8)113/180 (63)
Diarrhoea 14 (32)61/123 (49.6)4/4 (100)6/9 (66.7)85/180 (47.2)
Pale stools 13 (30)///13/44 (30)
Abdominal pain 12 (27)48/123 (39.0)7/9 (77.8)/69/176 (39)
Lethargy 10 (23)15/123 (12.2)4/4 (100)1/9 (11.1)30/180 (16.6)
Dark urine 6 (14)44/123 (35.8)//50/167 (30.0)
Coryza 6 (14)20/123 (16.3)/3/9 (33.3)29/176 (16.5)
Pyrexia 4 (9)51/123 (41.5)0/4 (0)5/9 (55.6)60/180 (33.3)
Pruritus 1 (2)///1/44 (2.0)
Anorexia65/123 (52.9)//65/123 (52.9)
Acute live failure6 (14)37/123 (30.1)/1/9 (11.1)44/176 (25)